Clinical Trial Update: Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating aflibercept after ranibizumab in exudative age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Wet Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)
• Ranibizumab (ranibizumab)

Snippet

Sponsor: Centre Hospitalier Intercommunal Creteil | Conditions: Macular Degeneration, Wet Macular Degeneration | Phase 3 | Status: COMPLETED